Issue release date: 12.11.2024
2Yeditepe University, School of Medicine, Department of Medical Biology, Istanbul, Turkey
3Istanbul Training and Research Hospital, Department of Neurosurgery, Istanbul, Turkey
4Halic University, School of Medicine, Department of Neurosurgery, Istanbul, Turkey
5Yeditepe University, School of Medicine, Department of Neurosurgery, Istanbul, Turkey DOI : 10.5137/1019-5149.JTN.35541-21.3 AIM: To determine expression levels of miRNA-582-5p and miRNA-363 in serum of patients with Glioblastoma Multiforme and assess their biomarker potential.
MATERIAL and METHODS: The study population consisted of 71 subjects including 35 patients and 36 healthy controls. Realtime polymerase chain reaction was used to determine serum expression levels of miRNA-582-5p and miRNA-363 in patients and control individuals. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic potential of miRNA-582-5p and miRNA-363. Serum caspase-9 level was measured using enzyme-linked immunosorbent assay.
RESULTS: Normalized expression levels of miRNA-582-5p and miRNA-363 were calculated using the 2???Ct method. We found that miRNA-582-5p and miRNA-363 were significantly upregulated in patients compared with healthy controls. High levels of miRNA- 582-5p (Fold change 2.86, p<0.0001) and miRNA-363 (Fold change 3.51, p<0.0001) were significantly associated with Glioblastoma Multiforme. Additionally, ROC analyses demonstrated that levels of miRNA-582-5p [area under the curve (AUC)=0.938, p=0.0001] and miRNA-363 [AUC=0.951, p=0.0001] were significantly different between the groups. In contrast, there was no correlation between levels of serum caspase-9 and those of miRNA-582-5p (p=0.144) or miRNA-363 (p=0.050).
CONCLUSION: High serum levels of miRNA-582-5p and miRNA-363 are associated with Glioblastoma Multiforme, and are potential biomarkers.
Keywords : Glioblastoma multiforme, miRNA-582-5p, miRNA-363, Biomarkers, Serum